Clinical Trial Update: Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC [Phase 3]

View source ↗

Summary

Phase 3 study to assess safety and efficacy of 177Lu-TLX250 in advanced relapsed or recurrent clear cell renal cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• 177Lu-TLX250 (TLX250)

Snippet

Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited | Conditions: ccRCC, Renal Cell Carcinoma (Kidney Cancer) | Phase 3 | Status: RECRUITING